PSA and the Future. Axel Heidenreich, Department of Urology
|
|
- Lillian Floyd
- 5 years ago
- Views:
Transcription
1 PSA and the Future Axel Heidenreich, Department of Urology
2 PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % PCPT-Studie Heidenreich A et al., Eur Urol 2011
3 Improvements of PSA EAU Guideline 2011 Improvement of PSA Specificity PSA - Density, Age specific reference values molecular PSA - variants (%f-psa, pro-psa) Limited value for PSA velocity (PSAV) and PSA doubling time (PSA DT) Heidenreich A et al., Eur Urol 2011
4 PSA Dynamics PSA velocity in men with total PSA < 4 ng/ml men with PSA <4 ng/ml Loeb et al.j Urol men with PCa and PSA-Velocity (ng/ml/year)
5 PSA Dynamcs PSA velocity in men with total PSA < 4 ng/ml Loeb et al.j Urol men with PSA <4 ng/ml 501 men with PCa and PSA-Velocity (ng/ml/year) PSAV %Sens %Spec %+pred %-pred 0,2 65% 70% 9% 98% 0,4 56% 83% 12% 98% 0,75 40% 92% 18% 97% 2% of men with PSAV <0,4ng/ml/year: PCa 13% of men with PSAV >0,4ng/ml/year: PCa
6 J Natl Cancer Inst 2011 AUC using multivariate model and analysis (age, PSA, DRE, family history, biopsy) with and w/o PSA velocity in 5519 men from PCPT PSA velocity improved area under the curve from to PSA velocity not helpful to identify patients with the need for a protate biopsy
7 J Natl Cancer Inst 2011 no evidence to support the recommendation that men with high PSA velocity should be biopsied in the absence of other indications PSA velocity should not be included in practice guidelines.
8 Free PSA Diagnostic Value of Free PSA among Men with PSA of <3 ng/ml. Finne et al. Eur Urol men with PSA <3ng/ml (Screening trial) median Follow-up 5,8 years 327 men with Pca Men with %f-psa <14% (lowest quartile) 6,9fold increased risk to harbour PCa as compared to men in the highest quartil (>23,7%)
9 National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Sturgeon CM Clin Chem Dec Recommendation to use %f-psa to differentiate between benign and malignant tissue if total PSA is <10 ng/ml. Recommendation to use %f-psa to differentiate between benign and malignant tissue if total PSA is <10 ng/ml CAVE: storing temperature
10 Prognostic Significance of PSA PSA serum concentration to predict the risk to develop metastases or to die from prostate cancer Catalona AUA 2008
11 Vickers et al. BMJ Sep 14
12 Vickers et al. BMJ Sep 14
13 Incidence and death from PCa in men with initial PSA <3.0 ng/ml: results from ERSPC Rotterdam (2) Bul M. Eur Urol Suppl 2011;10(2):145(abs.419) Hazard ratio of (aggressive) PCa and PCa death stratified by PSA group The risk of (aggressive) PCa and PCa-mortality in a screening population with initial PSA <3.0 ng/ml increases significantly with higher PSA levels
14 Biomarkers to detect PCA Pro PSA (Serum) PCA3 (Urin) prostate specific, non coding mrna EPCA-2 (Serum) nuclear structural protein measured by ELISA TMPRSS2-TTS Gen Fusion (Urine & tissue) Hypermethylation of gen (Urine) Genetische Risiko Varianten (Blut oder Abstrich) Catalona AUA 2008
15 PCA3 basic considerations Non-coding mrna Highly overexpressed in prostate cancer cells Can be isolated in urine after prostatic massage PSA mrna can also be isolated in urine after prostatic massage PCA3 score = PCA3 mrna PSA mrna x 1000
16 PCA3 molecular urine assay for PCa in men undergoing repeat biopsy. Marks et al. Urology Cells in prostatic urethra Digital Rectal Exam (DRE) First Catch Urine Specimen (20 30mL)
17 PCA3 score PCA3 can help to predict tumour volume P = 0.002; <0.5 cc vs cc <0.5 cc cc >2.0 cc Total tumor volume in prostatectomy specimens Nakanishi J Urol 179:1804,2008
18 PCA3 score better than other prognostic factors to predict small tumour volume Total Tumor Volume < 0.5 cc Variables AUC Asymptotic significance PCA3 score <0.001 PSA % positive cores Maximum tumor length Abbreviations: AUC, area under the curve; PSA, prostate specific antigen Nakanishi J Urol 179:1804,
19 PCA3 score PCA3 can help to predict tumor aggressiveness p = or greater Prostatectomy Gleason score Nakanishi J Urol 179:1804,
20 Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Haese et al. Eur Urol men examined: PCA3 Score did correlate with detection of prostate cancer in men who were scheduled for rebiopsies Score Sensitivity Specificity PCa3 Cut-off % 72 % PCa3 Cut-off % 82 %
21 Eur Urology2010
22 Critical Assessment of Preoperative Urinary PCA3 on the Accuracy of Prostate Cancer Staging no improvement to predict locally advanced prostate cancer Auprich et al. Eur. Urology 2010 Oct
23 Critical Assessment of Preoperative Urinary PCA3 on the Accuracy of Prostate Cancer Staging Improvement to predict insignificant prostate cancer Auprich et al. Eur. Urology 2011
24 1rst repeat Bx cohort, n = 48 (19 PCA, 29 no PCA) PCA score < 44 avoids 73% of unnecessary biopsies Auprich et al. BJU Int 2011
25 2nd repeat Bx cohort, n = 40 (13 PCA, 27 no PCA) %f PSA < 12% avoids 67% of unnecessary biopsies Auprich et al. BJU Int 2011
26 3rd repeat Bx cohort, n = 39 (12 PCA, 27 no PCA) %f PSA < 14% avoids 45% of unnecessary biopsies Auprich et al. BJU Int 2011
27 Prostate health index (phi): diagnostic accuracy (1) Catalona WJ. J Urol 2011:185(4 Suppl):e396(abs.982)» Multi-centre prospective case-control study» N=892 men 50 yr with PSA 2-10 ng/ml, non-suspicious DRE and biopsyconfirmed PCa diagnosis» tpsa, fpsa, [-2]proPSA determined using Beckman Coulter Access 2 Immunoassay Analyser; phi =([-2]proPSA/fPSA) x tpsa» Receiver operating characteristics (ROC) curve: Phi has higher clinical specificity than tpsa and %fpsa and may be used for aiding biopsy decisions in men with PSA 2-10 ng/ml and negative DRE
28 Prostate health index (phi): diagnostic accuracy (2) Nava L. J Urol 2011:185(4 Suppl):e919-0(abs.2293)» Single-centre prospective study; N=289 men undergoing TRUS-guided prostate biopsy (18-22 cores); PCa detected in 108 patients (37.3%)» phi =([-2]proPSA/fPSA) x tpsa (Beckman Coulter Access 2 Immunoassay Analyser)» Gleason score correlated with %[-2]proPSA (P<0.001) and phi (P<0.0001) Phi and %[-2]proPSA have higher specificity, sensitivity and diagnostic accuracy than reference standard tests and correlate with Gleason score
29 Summary for daily routine There is no PSA threshold levels which excludes PCA PSA remains a significant predictor for the presence and the biological aggressiveness of PCA Pro-PSA seems to be promising Use of PSA Dynamics highly controverial PCA3 to identify insignificant cancer?
30 Gene fusions and prostate cancer Gene fusions involving the prostate-specific gene transmembrane protease, serine 2 TMPRSS2 Gene fusions are only present in cancer cells or high grade PIN Morris et al BJU int 102:276, 2008
31 Gene Fusions in Prostate Cancer A Translocation ETV1 erythroblastosis virus transforming sequence Fusion Gene TMPRSS2:ETV1 Gene Fusion TMPRSS2 ERG (= oncogene) Chrom.21 Chrom.7 TMPRSS2 ERG (= oncogene) Occurs only in 1-10% of cases B Deletion Gene Fusion Fusion Gene TMPRSS2:ERG TMPRSS2 ERG (= oncogene) Deletion TMPRSS2 ERG (= oncogene) Occurs in 50% of cases Chrom.21 Tomlins et al., Science 310:644,2005 Chrom.21 31
32 Androgen Responsive Gene Fusions in Prostate Cancer TMPRSS2/GAPDH TMPRSS2/GAPDH TMPRSS2/GAPDH Fusion Structure Androgen Response Chromosome 21 Chromosome 7 TMPRSS2 ETV TMPRSS2:ETV1 R1881: + 20 TMPRSS2 ERG TMPRSS2:ERG R1881: + 20 TMPRSS2 ETV TMPRSS2:ETV4 R1881: + 32
33 HNRPA2B/GAPDH C15orf21/GAPDH Androgen Resistent Gene Fusions in Prostate Cancer Fusion Structure Androgen Response C15orf21 C15orf21:ETV1 ETV R1881: + Stimulates cancer progression in the androgenablation state HNRPA2B1 ETV HNRPA2B1:ETV1 R1881: + 33
34 Combination of PCA3 and TMPRSS2:ERG gene fusion: diagnostic accuracy Robert G. J Urol 2011:185(4 Suppl):e648(abs.1616)» Comparison of PCA3 and TMPRSS2:ERG expression levels (quantitative real-time PCR, normalised for housekeeping gene HPRT) between tissue samples of PCa (N=48), BPH (N=48) and normal tissue adjacent to PCa (N=32) Combination of PCA3 and TMPRSS2:ERG has a higher sensitivity and better accuracy than either test alone
35 Medical Faculty RWTH Aachen University, Pathology Workflow Spot isolation Material 1mm 2 n = 10/group Tryptic digest DIGE-technology Mass spectrometry Reverse phase protein array Western blot Protein I.D. urine/serumbiomarker? validation 1 cm G C 1 cm D
36 Non-invasive diagnosis of PCa: proteome analysis of seminal plasma Neuhaus J. Eur Urol Suppl 2011;10(2):206-7(abs.638)» Biomarker discovery and validation study in seminal plasma of men aged yrs with PSA 4-20 ng/ml or suspicious DRE» Discovery phase: accuracy of biomarker panel: 92%» Validation phase: Seminal plasma seems to be a suitable source for proteome based, non-invasive detection of PCa
37 The Belgian Shepherd Dog (Malinois) is a breed of dog, sometimes classified as a variety of the Belgian Shepherd Dog rather than as a separate breed. These dogs are popular in use of police departments, as are German Shepherds Eur Urol Oct 15
38 Eur Urol Oct 15
39 Correct identification of PCA in 30 of 33 cases 1/3 false negative patients was diagnosed with PCA on repeat biopsy Sensitivity and Specificity 91%. conclusion: urine contains PCA specific proteins => urine based screening potentially possible Eur Urol Oct 15
40
41 Ratio of the finger length Ratio of length of index finger to ring finger appears to be hormone dependent (2D:4D) Finger length ratio correlates negatively with the ratio of fetal estradiol levels to fetal testosterone levels
42 1524 men with PCA and 3044 controls Men with index finger longer as ring finger (high 2D:4D) 33% risk reduction to develop PCA (OR) 0.67, risk reduction in men <60 years (OR 0.13, 95% CI ). Finger length ration appears to be a simple biologic marker: 2D longer 4D: low risk
10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationHow to detect and investigate Prostate Cancer before TRT
How to detect and investigate Prostate Cancer before TRT Frans M.J. Debruyne Professor of Urology Andros Men s Health Institutes, The Netherlands Bruges, 25-26 September 2014 PRISM Recommendations for
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationThe Who s of Genomic Markers: Whom to Biopsy?
The Who s of Genomic Markers: Whom to Biopsy? 1.15.17 7:20-7:40 AM E. David Crawford, M.D. Professor of Surgery/Urology/ Radiation Oncology University of Colorado WSJ 5.10.16 2 Recent Advances in Prostate
More informationProstate cancer screening: a wobble Balance. Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph
Prostate cancer screening: a wobble Balance Elias NAOUM PGY-4 Urology Hotel-Dieu de France Universite Saint Joseph Epidemiology Most common non skin malignancy in men in developed countries Third leading
More informationThe use of PCA3 in the diagnosis of prostate cancer
The use of PCA3 in the diagnosis of prostate cancer Daphne Hessels and Jack A. Schalken Abstract Although the routine use of serum PsA testing has undoubtedly increased prostate cancer detection, one of
More information#1 cancer. #2 killer. Boulder has higher rate of prostate cancer compared to other areas surrounding Rocky Flats
Prostate cancer is a VERY COMMON DISEASE BREAKTHROUGHS IN THE DETECTION OF PROSTATE CANCER Carolyn M. Fronczak M.D., M.S.P.H. Urologic Surgery 303-647-9129 #1 cancer #2 killer Ca Cancer J Clin 2018;68:7
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationTowards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time
european urology supplements 8 (2009) 97 102 available at www.sciencedirect.com journal homepage: www.europeanurology.com Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationMP Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Medical Policy MP 2.04.33 BCBSA Ref. Policy: 2.04.33 Last Review: 11/15/2018 Effective Date: 02/15/2019 Section: Medicine Related Policies 2.04.111 - Gene Expression Analysis for Prostate Cancer Management
More informationExploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies
Exploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies Disclosures MDxHealth Scientific Advisor 2 Case Study 54-year-old man referred for a PSA of 7 - Healthy, minimal
More information2/5/2014. BIOMARKERS AND PROSTATE CANCER Can new biomarkers improve clinical decision making? Samir Bidnur PGY Feb
BIOMARKERS AND PROSTATE CANCER Can new biomarkers improve clinical decision making? Samir Bidnur PGY- 3 5- Feb- 2013 Objec-ves Review the need for new biomarkers in prostate cancer management Discuss the
More informationGenetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer Policy Number: 2.04.33 Last Review: 7/2017 Origination: 7/2014 Next Review: 7/2018 Policy Blue Cross and Blue
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationPredicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort
Predicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort MACIEJ SALAGIERSKI 1, PETER MULDERS 2 and JACK A. SCHALKEN 2 1 Urology Department, Medical University of Łódź, Poland;
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationClinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy
european urology 54 (2008) 1081 1088 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for
More informationDevelopment and Internal Validation of a Prostate Health Index Based Nomogram for Predicting Prostate Cancer at Extended Biopsy
Development and Internal Validation of a Prostate Health Index Based Nomogram for Predicting Prostate Cancer at Extended Biopsy Giovanni Lughezzani,*, Massimo Lazzeri, Alessandro Larcher, Giuliana Lista,
More informationProtein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer
Medical Policy Manual Laboratory, Policy No. 69 Protein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer Next Review: October 2018 Last Review: December 2017 Effective: January
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationGenetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer Policy Number: 2.04.33 Last Review: 7/2018 Origination: 7/2014 Next Review: 7/2019 Policy Blue Cross and Blue
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationPSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic and Protein Biomarkers for the Diagnosis Page 1 of 41 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Genetic and Protein Biomarkers for the Diagnosis
More informationMP Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Medical Policy MP 2.04.33 BCBSA Ref. Policy: 2.04.33 Last Review: 11/30/2017 Effective Date: 11/30/2017 Section: Medicine End Date: 02/14/2019 Related Policies 2.04.111 - Gene Expression Analysis for Prostate
More informationPSA screening. To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine
PSA screening To screen or not to screen, that s the question Walid Shahrour FRCSC, MDCM, BSc Assistant professor Northern Ontario School of Medicine Conflict of Interest Declaration: Nothing to Disclose
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Diagnosis and monitoring of prostate cancer: PROGENSA PCA3 assay and the Prostate Health Index (PHI) This overview summarises the key issues for the Diagnostics
More informationMr Declan Cahill Consultant Urological Surgeon The Royal Marsden
Diagnosing prostate cancer Mr Declan Cahill Consultant Urological Surgeon 2 Marsden GP Education Day 22 February 2016 Should I have a PSA test? Can I have a PSA test? prostatecanceruk.org 4 83% raised
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationTRUS Guided Transrectal Prostate Biopsy
TRUS Guided Transrectal Prostate Biopsy Will this be a technique of the past? Christopher Porter MD FACS, Virginia Mason Medical Center, Seattle Outline Will this book be obsolete? Old school Elevated
More informationProstate Cancer Screening: Navigating the Controversy
Prostate Cancer Screening: Navigating the Controversy 2 William M. Hilton, Ian M. Thompson Jr., and Dipen J. Parekh Despite advances in diagnosis, treatment, and patient outcomes, prostate cancer remains
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationAssociation of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer
Association of [ 2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer Jeffrey J. Tosoian,*, Stacy Loeb,*, Zhaoyong Feng, Sumit Isharwal, Patricia Landis, Debra J. Elliot,
More informationAdditional Disclosure
Additional Disclosure The Genetics of Prostate Cancer: Clinical Implications William J. Catalona, MD Collaborator with decode genetics, Inc. Non-paid consultant with no financial interest or support Northwestern
More information4/20/2015. Serum Protein Tumor Marker Assays: A Need for Constant Vigilance. Learning Objectives. Estimated Cancer Deaths in the US in 2015
Serum Protein Tumor Marker Assays: A Need for Constant Vigilance Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe what comprises an ideal
More information..biomarkers, running the gauntlet..
The long and winding round for the clinical introduction of a biomarker Molecular diagnostic of prostate cancer based on non invasive liquid biopsies..biomarkers, running the gauntlet.. Prof dr Jack A
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationDeveloping a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection
DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong
More informationDiagnosis and management of prostate cancer in the
Diagnosis and management of prostate cancer in the Jeremy Teoh ( 張源津 ) Assistant Professor, Department of Surgery, The Chinese University of Hong Kong. Email: jeremyteoh@surgery.cuhk.edu.hk Estimated age-standardised
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationTo be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?
To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationeuropean urology 55 (2009)
european urology 55 (2009) 385 393 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Is Prostate-Specific Antigen Velocity Selective for Clinically Significant
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationContribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationWhere are we with PSA screening?
Where are we with PSA screening? Faculty/Presenter Disclosure Rela%onships with commercial interests: None Disclosure of Commercial Support This program has received no financial support. This program
More informationQuestions and Answers About the Prostate-Specific Antigen (PSA) Test
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Questions and Answers
More information1. Benign Prostate Hyperplexia (BPH) 2. Prostate Cancer (PCa)
Objectives: Our first segment focused in the anatomy and functions of the prostate gland, to get a clear understanding of the male Genito-Urinary System. Now, we will explore two of the main problems associated
More informationSection Editors Robert H Fletcher, MD, MSc Michael P O'Leary, MD, MPH
1 de 32 04-05-2013 19:24 Official reprint from UpToDate www.uptodate.com 2013 UpToDate Author Richard M Hoffman, MD, MPH Disclosures Section Editors Robert H Fletcher, MD, MSc Michael P O'Leary, MD, MPH
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationProstate Biopsy in 2017
Prostate Biopsy in 2017 Bob Djavan, MD, PhD Professor and Chairman, Department of Urology, Rudolfinerhaus Foundation Hospital,Vienna, Austria Director Vienna Urology foundation Board member Scientific
More informationGene-Based Tests for Screening, Detection, and/or Management of Prostate Cancer
Medical Policy Manual Genetic Testing, Policy No. 17 Gene-Based Tests for Screening, Detection, and/or Management of Prostate Cancer Next Review: September 2019 Last Review: December 2018 Effective: January
More informationDebate: Genetics and Genomics should be used ONLY for re-biopsy
Debate: Genetics and Genomics should be used ONLY for re-biopsy Larry Goldenberg, CM, OBC, MD, FRCSC Professor, UBC Dept of Urologic Sciences Director of Development and Supportive Care, Vancouver Prostate
More informationObjectives. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Objectives Update
More informationContemporary Approaches to Screening for Prostate Cancer
Contemporary Approaches to Screening for Prostate Cancer Gerald L. Andriole, MD Robert K. Royce Distinguished Professor Chief of Urologic Surgery Siteman Cancer Center Washington University School of Medicine
More informationPCa Commentary. Volume 88 July - August THE VENERABLE PSA TEST: Sharpening Its Diagnostic Focus
1221 Madison Street, 1 st Floor Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 88 July - August 2014 CONTENT: PSA TEST Page 1 NEW AGENTS Page 5 THE VENERABLE PSA TEST: Sharpening
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationAssessment of Long-Term Outcomes Associated With Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion at Repeat Biopsy
Assessment of Long-Term Outcomes Associated With Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion at Repeat Biopsy Selin Merdan, MEng 1 ; Scott A. Tomlins, MD, PhD 2,3 ; Christine L. Barnett,
More informationNEGATIVE BIOPSIES WITH RISING PROSTATE-SPECIFIC ANTIGEN. WHAT TO DO?
NEGATIVE BIOPSIES WITH RISING PROSTATE-SPECIFIC ANTIGEN. WHAT TO DO? *Juan Gómez Rivas, 1 Mario Alvarez-Maestro, 1 Marcin Czarniecki, 2 Stefan Czarniecki, 3 Moises Rodriguez Socarras, 4 Stacy Loeb 5 1.
More informationProstate Cancer. Biomedical Engineering for Global Health. Lecture Fourteen. Early Detection. Prostate Cancer: Statistics
Biomedical Engineering for Global Health Lecture Fourteen Prostate Cancer Early Detection Prostate Cancer: Statistics Prostate gland contributes enzymes, nutrients and other secretions to semen. United
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationTumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer
Original papers Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer Tomaž Smrkolj 1, A F, Borut Gubina 1, B, E, F, Jure Bizjak 1, B, E, F, Kristina
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationTransrectal ultrasound-guided biopsy for the diagnosis of prostate cancer
Transrectal ultrasound-guided for the diagnosis of prostate cancer Adrian Haşegan Clinica de Urologie, Spitalul Clinic Judeţean de Urgenţă Sibiu Facultatea de Medicină Sibiu Abstract Transrectal ultrasound-guided
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationProstate Cancer. David Wilkinson MD Gulfshore Urology
Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)
More informationThe Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study
Asian Journal of Andrology (2016) 18, 925 929 2016 AJA, SIMM & SJTU. All rights reserved 1008-682X www.asiaandro.com; www.ajandrology.com Prostate Cancer Open Access ORIGINAL ARTICLE The Huashan risk calculators
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationHorizon Scanning Technology Briefing. Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer
Horizon Scanning Technology Briefing National Horizon Scanning Centre Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer December 2006 This technology summary is based on
More informationQuestions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test
Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test About Cancer Care Ontario s recommendations for prostate-specific antigen (PSA) screening 1. What does Cancer
More informationFinancial Disclosures. Prostate Cancer Screening and Surgical Management
Prostate Cancer Screening and Surgical Management Dr. Ken Jacobsohn Director, Minimally Invasive Urologic Surgery Assistant Professor, Department of Urology Medical College of Wisconsin Financial Disclosures
More informationProspective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort
European Journal of Cancer (2012) 48, 1809 1815 Available at www.sciencedirect.com journal homepage: www.ejconline.com Prospective validation of a risk calculator which calculates the probability of a
More informationComparative Assessment of Urinary Prostate Cancer
Papers in Press. Published December 4, 2012 as doi:10.1373/clinchem.2012.195560 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2012.195560 Clinical Chemistry 59:1 000 000
More informationBJUI. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
. JOURNAL COMPILATION 2010 BJU INTERNATIONAL Urological Oncology FOLLOW-UP OF MEN WITH AN ELEVATED PCA3 SCORE AND A NEGATIVE BIOPSY REMZI ET AL. BJUI BJU INTERNATIONAL Follow-up of men with an elevated
More informationSupplementary Material
Supplementary Material Identification of mir-187 and mir-182 as biomarkers for early diagnosis and prognosis in prostate cancer patients treated with radical prostatectomy Irene Casanova-Salas 1, José
More informationAn Approach to Early Detection of Significant Cancers
An Approach to Early Detection of Significant Cancers FDUS 9.11.16 E. David Crawford, M.D. University of Colorado Denver Aurora, CO AUA State of Art 2 WSJ 5.10.16 3 Recent Advances in Prostate Cancer:
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationPredictive role of free prostate specific antigen in a prospective active surveillance program (PRIAS)
World J Urol (2015) 33:1735 1740 DOI 10.1007/s00345-015-1542-3 ORIGINAL ARTICLE Predictive role of free prostate specific antigen in a prospective active surveillance program (PRIAS) Hanna Vasarainen 1
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Prostate-Specific Antigen (PSA) Screening for Prostate Cancer Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 12 References...
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationShould A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests?
Should A PSA threshold of 1.5 ng/ml be the threshold for further diagnostic tests? Hanan Goldberg, MD Princess Margaret Cancer Centre, UHN, Sunnybrook Health science Centre, University of Toronto, Toronto,
More informationPredictive Performance Evaluation
Predictive Performance Evaluation Clinical Performance of the 4Kscore Test to Predict High-grade Prostate Cancer at Biopsy: A Meta-analysis of US and European Clinical Validation Study Results Stephen
More informationBJUI. Study Type Prognosis (individual cohort study) Level of Evidence 2b OBJECTIVES CONCLUSIONS
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTING THE OUTCOME OF PROSTATE BIOPSY HERNANDEZ et al. BJUI BJU INTERNATIONAL Predicting the outcome of prostate biopsy: comparison
More informationPathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers
Pathologists Perspective on Focal Therapy: The Role of Mapping Biopsies and Markers M. Scott Lucia, MD Professor and Vice Chair of Anatomic Pathology Chief of Genitourinary and Renal Pathology Dept. of
More informationResearch Article External Validation of an Artificial Neural Network and Two Nomograms for Prostate Cancer Detection
International Scholarly Research Network ISRN Urology Volume 2012, Article ID 643181, 6 pages doi:10.5402/2012/643181 Research Article External Validation of an Artificial Neural Network and Two Nomograms
More informationRisk Migration ( ct2c=high)
Risk Migration ( ctc=high) Prostate Cancer Over- Detection, but Selective Treatment Active Surveillance Peter R. Carroll, MD, MPH Department of Urology University of California, San Francisco February,
More information